Biomarker-Guided Tailored Therapy in Major Depression
- PMID: 39261439
- DOI: 10.1007/978-981-97-4402-2_19
Biomarker-Guided Tailored Therapy in Major Depression
Abstract
This chapter provides a comprehensive examination of a broad range of biomarkers used for the diagnosis and prediction of treatment outcomes in major depressive disorder (MDD). Genetic, epigenetic, serum, cerebrospinal fluid (CSF), and neuroimaging biomarkers are analyzed in depth, as well as the integration of new technologies such as digital phenotyping and machine learning. The intricate interplay between biological and psychological elements is emphasized as essential for tailoring MDD management strategies. In addition, the evolving link between psychotherapy and biomarkers is explored to uncover potential associations that shed light on treatment response. This analysis underscores the importance of individualized approaches in the treatment of MDD that integrate advanced biological insights into clinical practice to improve patient outcomes.
Keywords: Biomarkers; Genetics; Machine learning; Major depressive disorder; Neuroimaging; Personalized medicine; Precision medicine.
© 2024. The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
References
-
- Al-Hakeim HK, Twayej AJ, Al-Dujaili AH, Maes M (2020) Plasma Indoleamine-2,3-dioxygenase (IDO) is increased in drug-Naï ve major depressed patients and treatment with sertraline and Ketoprofen normalizes IDO in association with pro-inflammatory and immune-regulatory cytokines. CNS Neurol Disord Drug Targets 19(1):44–54 - PubMed - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
